Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

658
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
658
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

443
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
443
Prodrugs01:30

Prodrugs

2.3K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Characterization of the genotypic and phenotypic spectrum of TCF7L2-related neurodevelopmental disorder (TRND).

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Correction: Quantify unmet medical need across the disease landscape - A large language model-based methodology.

PLoS medicine·2026
Same author

Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study.

American journal of hematology·2026
Same author

Breast-implant associated unicentric castleman disease: a case report.

Current problems in cancer. Case reports·2026
Same author

EpicTope: predicting and validating non-disruptive epitope tagging sites.

Development (Cambridge, England)·2026
Same author

Quantify unmet medical need across the disease landscape - A large language model-based methodology.

PLoS medicine·2026

相关实验视频

Updated: May 12, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K

罕见疾病药物重用 罕见疾病药物重用

Sally Nijim1,2, Ania Korsunska1, Joseph Zinski2

  • 1Castleman Disease Collaborative Network, Paso Robles, California.

JAMA network open
|May 5, 2025
PubMed
概括
此摘要是机器生成的。

罕见病非营利组织可以通过支持患者招募和提供非财政研究援助来提高药物重定向的成功率. 这些策略优化了缺乏FDA批准的治疗方法的罕见疾病的治疗方法.

更多相关视频

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.2K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.9K

相关实验视频

Last Updated: May 12, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.2K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.9K

科学领域:

  • 药物重用 药物重用
  • 罕见疾病 罕见疾病
  • 非营利组织 非营利组织

背景情况:

  • 超过9500种罕见疾病缺乏美国食品和药物管理局批准的疗法,需要创新的治疗策略.
  • 药物重定向提供了一个潜在的更快,更具成本效益的替代品新药开发,但面临重大障碍.
  • 罕见疾病非营利性组织 (RDNPs) 历来领导了重新定位的努力,但对其成功的系统数据有限.

研究的目的:

  • 描述当前罕见病药物重用倡议的现状.
  • 确定有助于成功药物重定向结果的关键因素.
  • 通过ROADMAP项目网络工具,为优化罕见病药物再利用提供主题见解.

主要方法:

  • 一项定性,混合方法的研究,涉及美国的RDNP和利益相关者.
  • 数据收集包括一项全国性调查和与RDNP领导人的半结构面试 (2021年9月 - 2022年1月).
  • 分析采用随机森林模型,以确定影响重新利用项目阶段和定性主题综合的因素.

主要成果:

  • 147个RDNP的调查回复表明,42%的药物参与了重新定位,其中94种药物处于不同阶段.
  • 成功的结局与非营利性支持的患者招募 (P < .001) 和非财务研究支持 (P = .02) 显著相关.
  • 开发了一个5个阶段的重定向框架,突出了从鉴定到临床实践优化的关键步骤.

结论:

  • 在促进罕见病药物重定向方面,RDNP起着至关重要的作用.
  • 优化系统性重新定位需要对患者招募和研究提供战略支持.
  • 该研究为RDNP,合作者和政策制定者提供了可操作的见解,以促进数据驱动的药物重新利用.